Oxford Asset Management LLP Makes New $39,000 Investment in Nevro Corp. (NYSE:NVRO)

Oxford Asset Management LLP bought a new position in shares of Nevro Corp. (NYSE:NVRO) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 10,577 shares of the medical equipment provider’s stock, valued at approximately $39,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. American Century Companies Inc. increased its position in Nevro by 12.9% during the 4th quarter. American Century Companies Inc. now owns 37,041 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 4,224 shares during the period. SG Americas Securities LLC raised its holdings in Nevro by 34.6% during the fourth quarter. SG Americas Securities LLC now owns 17,126 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 4,406 shares during the last quarter. Wells Fargo & Company MN boosted its position in Nevro by 29.9% during the fourth quarter. Wells Fargo & Company MN now owns 21,595 shares of the medical equipment provider’s stock worth $80,000 after purchasing an additional 4,971 shares in the last quarter. Virtu Financial LLC grew its holdings in Nevro by 59.9% in the fourth quarter. Virtu Financial LLC now owns 17,956 shares of the medical equipment provider’s stock valued at $67,000 after purchasing an additional 6,725 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Nevro by 62.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 20,548 shares of the medical equipment provider’s stock valued at $76,000 after buying an additional 7,889 shares in the last quarter. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Trading Up 0.1 %

Nevro stock opened at $5.85 on Tuesday. The stock has a market cap of $224.32 million, a PE ratio of -3.09 and a beta of 0.81. The stock has a 50-day moving average price of $5.81 and a 200 day moving average price of $5.05. Nevro Corp. has a 52 week low of $3.17 and a 52 week high of $11.79. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Tuesday, March 4th. The medical equipment provider reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.15. The firm had revenue of $105.55 million during the quarter, compared to analysts’ expectations of $102.61 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. Equities research analysts predict that Nevro Corp. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NVRO. StockNews.com began coverage on Nevro in a research note on Wednesday, April 23rd. They set a “hold” rating for the company. Piper Sandler raised Nevro from a “neutral” rating to an “overweight” rating and cut their price target for the stock from $6.00 to $5.85 in a research note on Friday, February 7th. Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and lifted their price target for the stock from $4.50 to $5.85 in a research note on Monday, February 10th. Finally, Canaccord Genuity Group lifted their price target on Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $5.36.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.